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Abstract
Background: Providers use risk-adjustment systems to help manage healthcare costs. Typically, ordinary
least squares (OLS) models on either untransformed or log-transformed cost are used. We examine the
predictive ability of several statistical models, demonstrate how model choice depends on the goal for the
predictive model, and examine whether building models on samples of the data affects model choice.
Methods: Our sample consisted of 525,620 Veterans Health Administration patients with mental health
(MH) or substance abuse (SA) diagnoses who incurred costs during fiscal year 1999. We tested two
models on a transformation of cost: a Log Normal model and a Square-root Normal model, and three
generalized linear models on untransformed cost, defined by distributional assumption and link function:
Normal with identity link (OLS); Gamma with log link; and Gamma with square-root link. Risk-adjusters
included age, sex, and 12 MH/SA categories. To determine the best model among the entire dataset,
predictive ability was evaluated using root mean square error (RMSE), mean absolute prediction error
(MAPE), and predictive ratios of predicted to observed cost (PR) among deciles of predicted cost, by
comparing point estimates and 95% bias-corrected bootstrap confidence intervals. To study the effect of
analyzing a random sample of the population on model choice, we re-computed these statistics using
random samples beginning with 5,000 patients and ending with the entire sample.
Results: The Square-root Normal model had the lowest estimates of the RMSE and MAPE, with bootstrap
confidence intervals that were always lower than those for the other models. The Gamma with square-
root link was best as measured by the PRs. The choice of best model could vary if smaller samples were
used and the Gamma with square-root link model had convergence problems with small samples.
Conclusion: Models with square-root transformation or link fit the data best. This function (whether
used as transformation or as a link) seems to help deal with the high comorbidity of this population by
introducing a form of interaction. The Gamma distribution helps with the long tail of the distribution.
However, the Normal distribution is suitable if the correct transformation of the outcome is used.
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The proportion of patients with Mental Health (MH) and
Substance Abuse (SA) disorders in the Department of Vet-
erans Affairs (VA) is higher than in other health care sys-
tems [1,2]. In fiscal year 1999 (FY99) (October 1, 1998 –
September 30, 1999), approximately 29% of the patients
were diagnosed with a MH/SA disorder. Moreover, while
the average number of unique diagnoses (including phys-
ical and psychiatric) in the general VA population is 9[3],
it is about 14 for patients with MH/SA disorders. Because
these patients are most likely to have high resource utili-
zation and consumption, adequate risk-adjustment mod-
els are needed to accurately predict MH/SA costs and to
better allocate resources among competing facilities and
networks within the VA.
Cost data typically present challenges because of their
skewness and high percentage of zeros. Two-part models
have been suggested as a method for solving the problem
where data contain a high percentage of zero costs[4,5].
However, obtaining good predictions with the condi-
tional model (the second part of the two-part model) is
crucial to the entire modeling process. Generalized linear
models (GLMs) are becoming increasingly more popular
but, depending on the choice of distribution and link
function, estimated effects of risk-adjustment measures
may not be additive or multiplicative, and thus, may be
difficult to understand and interpret. A commonly used
model for cost data is the Log Normal model. Here, the
cost is transformed into a logarithmic scale and ordinary
least squares (OLS) is performed on this new variable
making the effects multiplicative on costs. However,
transforming the dependent variable introduces retrans-
formation problems related to the original scale[6-8].
The method most recommended for predicting cost in the
health services literature, such as in "Risk Adjustment for
Measuring Health Outcomes," [9] is OLS on untrans-
formed cost. Transformation of the outcome or use of
GLMs are suggested as ways to handle extreme observa-
tions but the authors argue that it is important to keep
transparent modeling logic and that OLS is relatively
transparent. Although OLS offers transparency with
respect to easily understood additive effects, potential pre-
diction problems, e.g., negative cost estimates, are not as
transparent to the user of these systems. Also, while OLS
yields consistent estimates, it is less efficient than models
that explicitly take the skewness into account[7,10].
Sample sizes in many health economic cost studies pre-
sented to date vary widely, ranging from a low of 45[11]
to a high of 125,109[5]. Austin et al.[12] used a sample of
1,959 patients while Ai and Norton[13] and Buntin and
Zaslavsky[14] used samples of approximately 10,000 peo-
ple. Mullahy[15] used a sample of approximately 30,000
individuals. Our sample of about 500,000 patients is
therefore quite large compared to the samples used in the
above studies. Building a good predictive risk-adjustment
model requires large data sets and we found substantial
variation in sample sizes in model-building risk-adjust-
ment studies: from 35,000 to more than a million[16-21].
Kilian et al.[22] suggest that more studies are needed with
larger sample sizes and we found no other study that ana-
lyzes the implications of having smaller samples.
Two questions of interest arise: 1) Which statistical model
works best for our sample of over 500,000 patients if the
criteria for the prediction model are low root mean square
error (RMSE), low mean absolute prediction error
(MAPE), and predictive ratio (PR) around 1 for the entire
range of patient costs? and 2) Using these criteria, would
the best model for the entire sample be chosen as best if
small sample sizes are used? The focus in this paper is on
methods for assessing overall model fit and not on the
specific effects of the independent variables contained in
the risk-adjustment system.
Methods
Data description
VA administrative databases were used to select all veter-
ans with a MH/SA diagnosis (ICD-9-CM codes 290.00–
312.99, 316) and who used VA healthcare services in
FY99. All inpatient and outpatient diagnoses from FY99
were mapped into twelve MH/SA categories (Dementia/
Alzheimer's Disease, Alcohol Disorder, Drug Disorder,
Schizophrenia, Other Psychoses, Bipolar Disorder, Major
Depression, Other Depression, Posttraumatic Stress Dis-
order (PTSD), Anxiety Disorder, Adjustment Disorder,
and Personality Disorder). These categories are used in the
VA for mental health performance monitoring[23].
Depending on the diagnoses assigned, a patient can be
assigned to more than one MH/SA category.
The majority of VA patients do not pay for their care. The
Health Economics Resource Center (HERC), a national
VA center, has created estimated costs at the visit/stay level
using patient utilization data and cost data at the VA
department level. In order to calculate MH/SA costs, we
obtained all specialty MH/SA visits or any non-specialty
visit (e.g., primary care) for which a MH/SA diagnosis had
been assigned. Inpatient drug costs also are included in a
patient's annual cost value. A thorough description of the
cost data is found in Rosen et al.[24].
Model specification
Estimates from the models presented in Table 1 and
explained in more detail in the next section, were com-
puted using robust weighted generalized linear models.
All regression analyses were performed using Stata v8.2, in
particular, the glm command with the robust option. ThisPage 2 of 11
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individuals were part of a development sample used in the
study by Rosen et al. [24]. Our development sample com-
prised 60% of the total population (in Rosen et al. [24]),
and included 525,620 individuals having positive cost.
The independent variables included 20 age/sex categories
and 12 MH/SA categories. Corrections were necessary in
order to take into account patients who died during the
year and for whom full year data did not exist. Robust
regression was performed with the cluster option, where
the clusters were medical facilities where patients received
care. A patient was assigned to only one facility, defined
by the last non-missing facility recorded during FY99.
Adjustments were made in all models that forced the pre-
dicted mean to equal the observed mean (CN Morris
Smearing). Each predicted value was multiplied by a fac-
tor equal to the observed sum divided by the predicted
sum. Given that the VHA system operates under budgetary
constraints set by Congress, it is reasonable to incorporate
this property into all models.
Models
Cost data are non-negative and usually right-skewed.
These characteristics guide our choice of models for com-
parison. In addition, we consider models commonly used
in the literature.
Ordinary least squares (OLS) regression on cost is the
most common model used. It is the easiest to understand
because the independent variables have additive effects:
E{Y} = Xβ  (1)
where Y are independent Normal variables with constant
variance σ2. Predictions are given in the original scale  =
x . A property of all OLS models is that mean predicted
y always equals mean observed y and therefore no other
adjustement needs to be made. Because the Normal distri-
bution ranges from minus infinity to plus infinity, nega-
tive predictions are possible when applying this model.
Even though OLS is very popular, it does not directly deal
with the two characteristics of cost data: non-negative and
right-skewed. Transformation of the dependent variable
can sometimes solve these issues. In this paper we tested
two transformations: log and square root transformation.
The first case is commonly called a Log Normal model
and the independent variables have additive effects on the
log scale:
E{ln(Y)} = Xβ  (2)
where ln(Y) are independent Normal variables with con-
stant variance σ2. Retransformation is necessary in order
to get predictions on the original scale. However, direct
retransformation  gives biased estimates because
this assumes that E{ln(Y)} = ln{E(Y)}, which is not usu-
ally true. Several adjustments have been recommended to
deal with this problem [6,7]. Forcing the mean predicted
to equal mean observed and assuming the error term to be
homoscedastic corrects the bias predictions at the popula-
tion-level. It should also be noted that after retransforma-
tion all the additive effects in the log scale become
multiplicative effects in the original scale. Final predic-
tions in this model are given by
where 
Square-root transformation models are similar to the Log
Normal model in that retransformation is necessary to
yˆ
βˆ
ˆ
ˆ
y ex= β
ˆ
ˆ
y s ex= ⋅ ( )β 3
s y ex= ∑∑ / β
Table 1: Model's description
Model Name Dependent Variable Model Specification
Family Link v(μ) Equation
Normal with identity link (OLS) cost Normal Identity 1 E(Y) = xβ
Log Normal* ln(cost) Normal Identity 1 E{ln(Y)} = xβ
Sqrt Normal* Normal Identity 1
E{ } = xβ
Gamma with log link cost Gamma Log μ2 ln{E(Y)} = xβ
Gamma with square-root link cost Gamma Square Root μ2
 = xβ
* Transformation of dependent variable.
Note: μ = E(y) and V(μ) is variance function.
cost
Y
E Y( )Page 3 of 11
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model is specified as:
E{ } = Xβ  (4)
where  are independent Normal variables with con-
stant variance σ2. Direct retransformation gives  =
(x )2 and after forcing mean predicted to equal mean
observed, final predictions are given by
where . Squaring x  implicitly intro-
duces two-way interactions into the model.
Generalized linear models (GLMs) are a class of models of
the form g{E(Y)} = xβ, where g is called the link function
and Y has some distribution F[25]. The ordinary least
squares model is equivalent to a GLM where the distribu-
tion function is Normal and the link function is the iden-
tity. These models allow regression of several different
statistical distributions like Gamma or Binomial. Typi-
cally they are well defined by specifying a mean and a var-
iance function, as illustrated in Table 1, which are the first
two moments of any distribution. In contrast to the mod-
els where the dependent variable is transformed, retrans-
formation is not a problem and the estimated mean is
given directly by applying the inverse of the above func-
tion g:
Some authors have recommended the use of the Gamma
distribution in cost models [7]. This distribution can deal
with the long tail typically present in cost data. In this
paper, we test the Gamma model with the two link func-
tions also tested as transformations of the dependent var-
iable. Final predictions for the Gamma models are given
by
where  and g is either the log or the
square-root functions.
Model selection and validation
The models' predictive ability was evaluated using the
root mean square error (RMSE) and the mean absolute
prediction error (MAPE). These are common statistics
used to assess models in the risk-adjustment and health
economics literature[8,12,14,21]. Defining yi as the
observed cost and  as the predicted cost for an individ-
ual then
and
Large values indicate a poor fit. To further test each
model's performance, we also looked at predictive ratios
(PRs), which are a group-level type of measure [26]. These
were computed for deciles of predicted cost. For a decile j,
the PR is the ratio of predicted cost to observed cost
among patients in each decile. The closer the values are to
1.0, the better the model prediction is within that decile.
Following the method by Kilian et al.[22] we computed
bias-corrected bootstrap confidence intervals for each one
of these measures to help with the comparison of the dif-
ferent models. This was done using the bootstrap com-
mand in Stata using 1000 replications and the strata
option to allow for independent sampling within each
facility.
Sample size study
Data access problems, costs, and other obstacles often
limit the amount of data available for building a risk
adjustment model. To study the effect of developing the
model on a subset of the data, we examined the effect of
sample size on model choice using randomly selected
samples of various sizes. We sought to answer the ques-
tion: is model choice affected by the size of the sample
used? We varied sample sizes between 5,000 and the
entire sample. However, the results for samples above
80,000 were very stable. For each size, we randomly
selected 100 samples, ran all five models, and computed
all the statistical measures mentioned above (RMSE,
MAPE, and PRs by decile of predicted cost). We compare
95% percentile confidence intervals of each measure
within each sample size for all five models.
Results
The total sample consisted of 525,620 patients; 95% were
males, with a mean age of 57 years (SD = 14.0); about
30% were age 65 and older. The dependent variable, total
MH/SA cost, had a mean of 2,602 (SD = 11,052), a
median equal to 385, and a skewness of 14. The residual
plot from the Normal Identity model indicated hetero-
scedasticity and the QQ plot showed non-normality of
the error term. The QQ plot of the residuals from the Log
Y
Y
yˆ
βˆ
ˆ ( ˆ)y s x= ⋅ ( )β 2 5
s y x= ∑∑ / ( )β 2 βˆ
ˆ ( ˆ)y g x= ( )−1 6β
ˆ ˆy s g x= ⋅ ( )−1 7β
s y g x= −∑∑ / 1 β
yˆi
RMSE
n
y yi i
i
n
= − ( )
=
∑1 82
1
( )
MAPE
n
y yi i
i
n
= − ( )
=
∑1 9
1
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values for costs in the Normal Identity model took on
negative values for 19.6% of the total sample.
Table 2 summarizes the overall performance of the mod-
els including bootstrap confidence intervals (BCIs). The
Square-root Normal model had a RMSE of 9,860 and a
MAPE value of 2,554, the lowest of all five models. More-
over, its bootstrap confidence intervals were lower than
any other BCI. The OLS model and the Gamma with
square-root link model had the second best RMSEs, with
both estimates and BCIs very close in value. The Gamma
with square-root link and the Log Normal model pre-
sented the second best estimates for the MAPE, also with
very close BCIs. For both measures, the Gamma Log
model performed the worst, with a RMSE twice the value
of the RMSE for Square-root Normal model and with con-
fidence intervals that are outside the bounds of all other
models' BCIs.
Inspection of the PRs among deciles of predicted total
MH/SA cost (see Figure 1) indicates that only the Gamma
Square Root model performed reasonably well, with PRs
close to 1.0 (values ranging from 0.90 to 1.18) across all
10 deciles. Moreover, the BCIs included 1.0 for five of the
deciles (deciles 2, 4, 5, 8, and 9). The Normal Identity
model (OLS) had two BCIs that included 1.0 (deciles 5
and 10). However, it had negative PRs for the first two
deciles because of the 20% negative predictions, and for
the remaining eight the values ranged from 0.54 to 1.46.
The Log Normal model did well in the first decile, but
either underpredicted or overpredicted by more than 25%
for the remaining nine deciles (values ranging from 0.30
to 1.69). The Square-root Normal model had values rang-
ing from 0.9 to 1.18, with BCIs that never included 1.0.
The Gamma Log model underpredicted substantially in
the first nine deciles (values ranging from 0.33 to 0.66)
and overpredicted in the top decile (2.04) with BCIs that
also never included 1.0.
Sample size study
The Gamma with square-root link model had conver-
gence problems with the smallest samples. The frequen-
cies of samples for which models did not converge, ranged
from 1 (sample with 55,000 patients) to 50 (samples with
5,000 patients) out of 100 replications within each sam-
ple size tested. There were three categories for which this
problem occurred the most and they were for females in
three age groups: 70–74, 80–84, and 85 or older. Each one
of these groups had, in the overall sample, 74, 70, and 35
patients, respectively. When resampling, these small
groups become extremely small, with categories having
only 1 or 2 patients after sampling. Even though the pro-
cedure had problems converging when fitting the Gamma
with square root link, this did not present a problem for
the other four statistical models.
Figure 2, 3, and 4 shows 95% percentile intervals from
each simulation of sample sizes starting at 5,000 up to
80,000 patients, for three measures: RMSE, MAPE, and the
predictive ratio for decile 10, which includes 10% of the
patients having the highest predicted cost. In Figure 2, the
Gamma with square-root link and OLS models have
mean estimates and percentile intervals for the RMSE that
are very similar for all sample sizes tested. The interval
overlap of these models and the one for the Square-root
Normal model decreases as the sample size increases.
These three models show the lowest RMSE values. The
percentile interval for the Log Normal model overlaps
with other three intervals for samples with 5,000 patients.
The intervals for the Gamma with log link model are
always higher than the intervals for the Gamma with
square-root link, OLS, and Square-root Normal models. If
the criterion for model selection is to choose the one with
smallest RMSE, OLS and Gamma with square-root link
could also be chosen, besides the Square-root Normal
model which gives the smallest RMSE in the full sample.
In Figure 3, we see a bigger overlap between all models.
For samples with 5,000 patients, all percentile intervals
overlap. The square-root normal model intervals have
consistently the smallest lower bound and for samples
Table 2: Root mean square error (RMSE) and mean absolute prediction error (MAPE) results obtained for the 5 models run in the full 
sample of 525,620 patients
Model RMSE MAPE
Estimate 95% Conf. Int.* Estimate 95% Conf. Int.*
Normal with Identity link (OLS) 10,397 10,130 10,657 2,997 2,941 3,052
Log Normal 13,974 13,585 14,352 2,801 2,759 2,840
Sqrt Normal 9,860 9,644 10,070 2,554 2,514 2,592
Gamma with log link 21,374 20,246 22,552 3,324 3,249 3,395
Gamma with square-root link 10,434 10,193 10,708 2,797 2,744 2,859
* Bias-corrected bootstrap confidence intervalPage 5 of 11
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BMC Medical Research Methodology 2006, 6:53 http://www.biomedcentral.com/1471-2288/6/53Predictive ratios (PR) per decile of predicted cost in full sample (N = 525,620)Figure 1
Predictive ratios (PR) per decile of predicted cost in full sample (N = 525,620). PR is computed as the ratio of pre-
dicted cost to observed cost for deciles of predicted cost. For each decile, PR = 1 when mean predicted cost equals mean 
observed cost. Also shown, are 95% bias-corrected bootstrap confidence intervals.
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with at least 15,000 patients the upper bound is always
smaller than the average MAPE of all other 4 models. As
the sample size increases, the upper bounds of the inter-
vals for the Square-root Normal model become smaller
and isolated from the other models. However, for smaller
sample sizes, one could pick both the Log Normal and
Gamma with square-root link models as giving the lowest
MAPE, even though it is the Square-root Normal model
that has the smallest MAPE in the full sample.
For samples with 5,000 patients, both the Gamma with
square-root link and OLS models have percentile intervals
for the predicted ratio in decile 10 that include 1.0 (see
Figure 4). This means that for some samples, these models
give a predicted mean close to the observed mean for
those predicted to be in the top decile. The Square-root
Normal model has intervals that overlap more for 5,000
patients and less up to 15,000 patients. However, these
intervals are the smallest for all models. Intervals for the
Gamma with log link and Log Normal models are always
higher than the intervals for all other three models.
Discussion
This analysis used five statistical models to predict cost for
a population of patients with MH/SA disorders in the VA.
Several methods for overall model fit, as well as fit within
deciles of predicted costs, were used to test the predictive
ability of the models. Moreover, a test of sensitivity of
model choice to sample size was performed using simula-
tion methods.Page 6 of 11
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BMC Medical Research Methodology 2006, 6:53 http://www.biomedcentral.com/1471-2288/6/5395% root mean square error (RMSE) percentile intervals per model at each simulation of various sample sizesFigu e 2
95% root mean square error (RMSE) percentile intervals per model at each simulation of various sample sizes. 
 Large values indicate a poor fit. The simulations at each sample size are based on 100 samples 
with the exception of the simulations for the Gamma Square Root model. Samples for which the model did not converge are 
dropped: 50 when sampling 5,000 subjects, 15 for 10,000, 16 for 15,000, 8 for 20,000, 7 for 25,000 and 30,000, 5 for 35,000, 
and 1 for 50,000 and 55,000.
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Ordinary least squares is often used to regress cost on
patient characteristics. The population tested in this study
has multiple comorbidities, with some patients (or a large
proportion) incurring very high costs. This causes the tail
of the distribution of costs to be very right-skewed and
residuals from the model are not distributed normally.
Nevertheless, even for distributions that account for long
tails, often there are not enough observations with
extremely high values to estimate the tail accurately.
The sample used in this study is large (more than 10 times
larger than what is reported for other studies) and allows
for extensive study of how well each of the models predict
and also how well they predict for smaller sample sizes.
This is of extreme importance, given that in many studies,
researchers do not have access to such large datasets or for
other reasons cannot analyze data from an entire popula-
tion.Page 7 of 11
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BMC Medical Research Methodology 2006, 6:53 http://www.biomedcentral.com/1471-2288/6/5395% mean absolute prediction error (MAPE) percentile intervals per model at each simulation of various sample sizesFigure 3
95% mean absolute prediction error (MAPE) percentile intervals per model at each simulation of various sam-
ple sizes.  Large values indicate a poor fit. The simulations at each sample size are based on 100 
samples with the exception of the simulations for the Gamma Square Root model. Samples for which the model did not con-
verge are dropped: 50 when sampling 5,000 subjects, 15 for 10,000, 16 for 15,000, 8 for 20,000, 7 for 25,000 and 30,000, 5 for 
35,000, and 1 for 50,000 and 55,000.
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The Gamma Log model was found to be the worst model
in every statistic analyzed. It did particularly poorly for the
RMSE, with a value that was more than double the small-
est RMSE value corresponding to the Normal Identity
model. It also performed poorly for deciles of predicted
cost, underpredicting consistently for the first 9 deciles
and overpredicting in the 10th decile.
Nixon and Thompson [11] conclude that skewed para-
metric distributions fit cost data better than the Normal
distribution. In our sample, the Normal Identity model
performed well, as shown by the measures of the predic-
tions in the full sample. The Normal Identity had the sec-
ond smallest RMSE and a predictive ratio for the top decile
not statistically different from 1. The major problem with
this model is the extremely large percentage of negative
predictions it generates. If all one is interested in is the
overall mean prediction, then the model is adequate.
However, if one is interested in individual predictions,
such as those patients with small costs, the model is not asPage 8 of 11
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95% predicted ratio for decile 10 (PR10) percentile intervals per model at each simulation of various sample 
sizes. PR is computed as the ratio of predicted cost to observed cost whithin decile 10 of predicted cost. PR = 1 when mean 
predicted cost equals mean observed cost. The simulations at each sample size are based on 100 samples with the exception of 
the simulations for the Gamma Square Root model. Samples for which the model did not converge are dropped: 50 when sam-
pling 5000 subjects, 15 for 10,000, 16 for 15,000, 8 for 20,000, 7 for 25,000 and 30,000, 5 for 35,000, and 1 for 50,000 and 
55,000.
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good. Nonetheless it performed reasonably well at the top
deciles, which is often an important target group for pol-
icy makers and disease management planners.
The models tailored to deal with the skewed sample per-
form reasonably well. In the overall sample, models with
square-root transformation or link perform the best. This
could be due to the fact that the square root transforma-
tion forces a form of interaction among the independent
variables that might be needed in this sample because
many of the patients have multiple MH/SA conditions.
Interactions usually are not used in risk-adjustment sys-
tems except for systems that use hierarchies within condi-
tions. However, hierarchies are a limited form of
interactions and are designed primarily to avoid double
counting specific diagnoses within a disease category, e.g.,
for a patient with paranoid schizophrenia and psychoses
NOS ("not otherwise specified"), only the paranoid schiz-
ophrenia is counted. The Square-root Normal model has
the smallest MAPE and RMSE that are statistically differ-
ent from the other models values. The Gamma with
square-root link has PRs that are (for each decile) consist-
ently very close to 1.
The Log Normal is a multiplicative model. It does well
when assessed on the log scale (not shown here) but afterPage 9 of 11
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poorly. One reason is the fact that we are using a sample
of all MH/SA patients, which are, in general, a highly
comorbid population within the VA. Those individuals
most comorbid are the ones found in the upper deciles.
When bringing predictions back to the original scale, the
multiplicative effect in this model causes large predictions
as evidenced by an extremely high PR in the 10th decile.
The overprediction in the 10th decile, together with the
fact that we are forcing the mean predicted to equal the
mean observed, translates into very poor predictions in
the middle deciles.
Simulation results show that even though on average
results do not differ from those in the larger sample,
gamma models have some convergence problems for
smaller sample sizes. However, this problem is directly
related to the extremely small number of subjects in cer-
tain cells. This can be dealt with by inspecting the data
before running the model. In the case of obtaining a sam-
ple with very small numbers for certain categories, the
investigator should consider combining categories with
small cell sizes before deciding that gamma models can-
not be run. In the sample presented, the Gamma with
square-root link model gives a very good fit in the overall
sample; even for the small samples where the model con-
verges, this is a reasonable choice based on the statistics
we assessed.
Choosing a parsimonious model is an important statisti-
cal practice. This argument often is used to justify the
choice of OLS risk-adjustment models. However, parsi-
mony requires that the model be the simplest one possi-
ble that also fits the data well. The large percentage of
negative predictions from our OLS models invalidates, in
this study, this characterization for the OLS model.
More advanced models have been introduced in the liter-
ature that are an extension of the GLM models. Basu and
Rathouz 2005 [27] introduce a method that directly esti-
mates the link function in a GLM from the data. Manning,
Basu, and Mullahy 2005 [28] describe the generalized
Gamma models, which include the OLS with Normal
error, OLS for Log Normal, and Gamma with a log link as
special cases. One limitation of our study is that we com-
pared models using one risk-adjustment system. The pop-
ulation of interest and the goals for the risk-adjustment
system dictate our choice of the best model for this set-
ting. So, although the model choice may not generalize to
other risk-adjustment systems, the process of defining
goals and testing whether the model meets the goals is
generalizable to good statistical practice.
Conclusion
This work provides further statistical information on
model performance and model choice for risk-adjustment
models used for predicting costs in patients with MH/SA
diagnoses. We use one MH/SA risk-adjustment system
and compare five different statistical models. We found
that the models with square-root transformation or link
performed best in the full sample. This function (whether
used as transformation or as a link) seems to help deal
with the high comorbidity of this population by introduc-
ing a form of interaction. The Gamma distribution is
modeling the variance better, as seen in better predictions
throughout all 10 deciles. However, the Normal distribu-
tion is suitable if the correct transformation (square-root
in our case) of the outcome is used and this should be true
when this method is applied to highly comorbid popula-
tions. For smaller samples, the Gamma with square-root
link model had problems converging. However, this was
directly tied to very small numbers in certain categories
and this can be solved by collapsing some of the catego-
ries. OLS on untransformed cost and the Log Normal and
Square-root Normal model are relatively unaffected by
the sample size for the criteria we used, while the GLMs
assuming a Gamma distribution are less consistent for
smaller sample sizes.
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